The European Summit for Clinical Nanomedicine and Targeted Medicine - The Translation to Knowledge Based Nanomedicine
Eighth Conference And Exhibition, June 28 - July 1, 2015
Sunday, June 28, 2015 • General Assembly of the European Society for Nanomedicine (15.30 h)
Co-founded by the Swiss Confederation. Swiss Derpartment of Economic Affairs, Education and Research
Scientific Committee: • Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH) (Chairman) • Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL) • Dr. med. h.c. Beat Löffler, MA, European Foundation for Clinical Nanomedicine (CLINAM), Basel (CH) • Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, (NL) • Prof. Dr. Marisa Papaluca Amati, European Medicines Agency, London (GB) •Prof. Dr. med. Janos Szebeni, Bay Zoltan Ltd and Semmelweis/Miskolc Universities, Budapest (HU) • Prof. Dr. med. Christoph Alexiou, Head and Neck Surgery, University Hospital Erlangen (D) • Prof. Dr. Claus-Michael Lehr, Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarbrucken (D) • Prof. Dr. Gerd Binnig, Founder of Definiens AG, Nobel Laureate, Munich (DE) Patrick Boisseau, CEA-Léti, Chairman of the ETPN, Grenoble (FR) • Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zürich (CH) • Prof. Dr. Jan Mollenhauer, Director Lundbeckfonden Center of Excellence University of Southern Denmark, Odense (DK) Dr. Yanay Ofran, Systems Biology & Functional Genomics, Bar Ilan University, Ramat Gan (IL)
The CLINAM‐Foundation and its collaborators for the conference have the pleasure to announce the European Summit for Clinical Nanomedicine and Targeted Medicine in Basel. The meeting has become a worldwide interdisciplinary Nanomedicine platform with more than 500 participants from 42 countries joining the last Summit in 2014. CLINAM’s major goal is to support of development and application of Nanomedicine and Targeted Medicine from the stage of basic research all the way to the clinics for the benefit of the patient and humankind. The CLINAM Summit has achieved a unique position in bringing together all stakeholders in field of Nanomedicine and Targeted Medicine, including regulatory authorities from all continents, clinicians, researchers and industrial innovators.
The CLINAM Summit has emerged as valuable interaction place to launch collaboration, get new ideas and learn about novel methodologies and technologies as well as novel projects, including numerous EU‐wide efforts, in Nanomedicine
and Targeted Medicine. The field represents one of the most exciting and promising arenas for novel technologies, assisting to combat devastating diseases in developing and industrialized countries and to generate novel concepts for addressing the challenges associated with demographic changes in the European society and World‐wide. Nanomedicine and Targeted Medicine are the catalyst disciplines for developing diagnostics and treatments accounting for the nanoscale, molecular and cellular origin of disease and one of the enabling disciplines for the Knowledge‐Based Medicine of tomorrow.
Translation from Innovation to Product
The pathway from the innovative idea to the application, the development, regulatory approval and commercialization of nanomedical drugs is complex and first and primarily requires understanding the cause of the disease. The nature of
nano‐drugs and their use require high level of knowledge in many other disciplines including physics, chemistry, pharmacy biology, engineering and nanotechnology. A cross talk between all these disciplines is a “must”. The translation process from research findings to applications in Nanomedicine and Targeted Medicine has been well developing and is now on the agenda of the global players in the pharmaceutical industry. The decision makers in pharmaceutical companies start appreciating the quality and potential of Nanomedicine and Targeted Medicine for significantly increasing the output of diagnostics and therapeutic products, which are less invasive and possess reduced side effects. By bringing the relevant stakeholders together, the CLINAM Summit has achieved an actively promoting role in this process.
Towards Personalized Medicine
In the next decades, medicine will experience a transformation to personalized diagnosis and treatment, taking the individual aspects of the patient and his/her disease into consideration. Key roles play high‐resolution molecular profiling techniques having been enabled, and have been made inexpensive by Nanomedicine. The CLINAM Summit offers excellent opportunities for the huge number of organizations, which are worldwide working towards this goal, to exchange expertise and to launch joint ventures for further acceleration of the process.
The Three Medical Focus‐Fields for 2015
As all years, the scientific committee votes for 3 fields in medicine to be extra focused on. For this Summit, the topics chosen are ● Infection and Inflammation ● Cancer and ● Metabolic Disease / Diabetes. Why to Participate in the CLINAM Summit At CLINAM 8/2015, speakers will have the unique opportunity to highlight and discuss their work with experts from the different fields that comprise Nanomedicine and Targeted Medicine, including regulatory authorities, industrial,
academic, and clinical experts. CLINAM is the most comprehensive feedback that you can obtain. Leading Exhibitors will show their novel equipment and concepts and promote the interaction between industry and the researching and developing community.
The Board of the CLINAM Foundation is grateful for the collaboration with many organizations that are willing to bring into this meeting highly skilled expertise and make the Summit to an international melting pot for the medicine of the future on the background of a neutral platform provided by the non-for-profit Foundation for Clinical Nanomedicine (CLINAM) in Basel.
The European Foundation for Clinical Nanomedicine is a non-profit institution aiming at advancing medicine to the benefit of individuals and society through the application of nanoscience. Aiming at prevention, diagnosis, and therapy through nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focussed research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders. The recognition of the large future impact of nanoscience on medicine and the observed rapid advance of medical applications of nanoscience have been the main reasons for the creation of the Foundation.
Nanotechnology for Medicine
Nanotechnology is generally considered as the key technology of the 21st century. It is an interdisciplinary scientific field focusing on methods, materials, and tools on the nanometer scale, i.e. one millionth of a millimeter. The application of this science to medicine seeks to benefit patients by providing prevention, early diagnosis, and effective treatment for prevalent, for disabling, and for currently incurable medical conditions.